The microscopic pathogen that is threatening global health and wreaking havoc from Singapore to Seoul, Tokyo to New York and Berlin to Milan is clearly reshaping the 2020 global outlook. But it should not derail the current momentum driving sustainability investing and corporate governance.
Medicine in the Age of Pandemics: why our innovation system for new drug discovery is failing and how to fix it
Covid-19 is our wake-up call. Deadly pandemics are expected to keep growing in the future and our innovation system for life-saving drug development is ill equipped to deal with it. Here is why and how to fix it.
The ongoing Covid-19 crisis can probably be seen as a “black swan” not only for China but also the whole world. It is largely unpredictable but with severe consequences.
There is no doubt that China has suffered the most from this crisis economically, socially and politically. However, it is highly debatable whether China or the Communist Party is approaching an inflection point of possible breakup or imminent revolution.
The outbreak of the 2019 novel coronavirus is so potentially impactful that we are devoting this entire edition to the epidemic, to an attempt to gauge its seriousness. Some stories are so big that it is hard to get your arms around them and this one definitely fits that category. Social media wasn't a factor during the 2003 SARS epidemic. The Chinese economy was a much smaller percentage of global GDP, and travel to and from China was far less common. So a simple comparison to SARS is not enough.
Co-authored with Jeff Jones, Chief Commercial and Strategy Officer for Conifer Health Solutions.
Co-authored with John Kerins, Director in Cain Brother’s Corporate M&A Advisory practice.
Our subject is health - both the health of the global economy, and the health of its global citizens. Each is dependent on the other, especially in a world where healthcare expenditures continue to rise. According to the World Bank, they average ten percent of GDP and are nearly double that in the US.